What is William Blair’s Estimate for Hologic Q1 Earnings?

Hologic, Inc. (NASDAQ:HOLX) – Research analysts at William Blair cut their Q1 2025 EPS estimates for Hologic in a note issued to investors on Monday, November 11th. William Blair analyst A. Brackmann now forecasts that the medical equipment provider will post earnings of $1.00 per share for the quarter, down from their prior forecast of $1.02. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. William Blair also issued estimates for Hologic’s FY2026 earnings at $4.62 EPS.

HOLX has been the subject of several other research reports. Raymond James lifted their price target on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. boosted their target price on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Leerink Partners cut their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Mizuho decreased their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Finally, StockNews.com downgraded Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Stock Performance

Hologic stock opened at $79.18 on Wednesday. The stock has a fifty day moving average price of $80.84 and a 200 day moving average price of $78.22. Hologic has a 52 week low of $67.59 and a 52 week high of $84.67. The firm has a market capitalization of $18.39 billion, a P/E ratio of 23.78, a PEG ratio of 2.52 and a beta of 0.98. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same period in the previous year, the firm posted $0.89 EPS. Hologic’s revenue was up 4.5% on a year-over-year basis.

Hedge Funds Weigh In On Hologic

A number of institutional investors and hedge funds have recently bought and sold shares of HOLX. Price T Rowe Associates Inc. MD boosted its stake in shares of Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after purchasing an additional 2,753,016 shares during the period. FMR LLC lifted its holdings in Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after buying an additional 2,174,093 shares in the last quarter. Swedbank AB purchased a new position in Hologic in the 1st quarter valued at about $120,827,000. Black Creek Investment Management Inc. grew its stake in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after acquiring an additional 885,524 shares in the last quarter. Finally, Mackenzie Financial Corp increased its position in shares of Hologic by 1,023.3% during the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after acquiring an additional 815,960 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.